Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)
Close on Nov 17, 2026Market cap $8.34MP/E –Yield –
Vistagen Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Vistagen Therapeutics's price to sales ratio was 3.1× on Nov 11, 2026, against 98.3× a year earlier. Over the last 5 years it ranged from 2.7× to 331.1×, with a median of 78.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.1× | −99.6 |
| 2025 | Apr 30, 2025 | 102.6× | +0.5 |
| 2024 | Dec 31, 2024 | 102.1× | +52.3 |
| 2023 | Dec 29, 2023 | 49.8× | +25.1 |
| 2022 | Oct 31, 2022 | 24.7× | −178.0 |
| 2021 | Dec 31, 2021 | 202.7× | −100.3 |
| 2020 | Dec 31, 2020 | 303.0× | +290.7 |
| 2017 | Jul 31, 2017 | 12.4× | −51.1 |
| 2013 | Jul 31, 2013 | 63.4× | +45.4 |
| 2012 | Dec 31, 2012 | 18.1× | −7.6 |
| 2011 | Dec 30, 2011 | 25.7× | – |
See a number that looks wrong?